RNS Number:2579P
Alliance Pharma PLC
10 January 2007

For immediate release                     10 January 2007

                              ALLIANCE PHARMA PLC

                      ("Alliance Pharma" or "the Company")

                               Board Appointment

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company, is pleased to announce that Mark John Tomlinson has been appointed as Medical
Director and that he will join the Company's Board with immediate effect as an Executive Director.

Dr Tomlinson MB BCh, age 44, is a highly experienced pharmaceutical physician with an international track record in the pharmaceutical industry where he has a particular expertise in the management of clinical research projects and preparing products for market.

Dr Tomlinson has worked at major pharmaceutical groups including Bristol-Myers Squibb, where he held positions in the UK and US between 1996 and 2001, and at Sanofi-Synthelabo, where he held the position of Head of Medical Affairs in the UK during 2001 and 2002. Most recently Dr Tomlinson held the position of Medical  Director at Sequani Ltd, a clinical research organisation based in the UK which he joined in 2003.

In parallel with his career in the pharmaceutical industry Dr Tomlinson has continued his involvement with clinical practice in various part-time and consultancy roles including acting as a GP Appraiser between 2003 and 2005 for the Herefordshire Primary Care Trust.

Dr Tomlinson's appointment to the newly formed position of Medical Director at Alliance Pharma will add significantly to Alliance's resources as it pursues the development of Posidorm, its melatonin product for sleep disorders, and Isprelor, its intra-vaginal misoprostol product for the induction of labour.

Michael Gatenby, Alliance Pharma's Chairman, said: "I am delighted to welcome Mark both to Alliance Pharma and to the Board. His breadth of experience gained internationally in the pharmaceutical industry will be of significant value to the Company's future development."

There are no further disclosures to be made in accordance with Schedule 2 (g) of the AIM rules.

For further information:
Alliance Pharma plc         + 44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk
--------------------------

Buchanan Communications    + 44 (0)20 7466 5000

Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or shares, the rights to 34 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal infections, in the treatment of dermatological conditions and in childbirth.  Alliance Pharma's sales are mainly prescription driven. Its products are istributed to hospitals directly and to pharmaceutical wholesalers which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma is also developing novel products for sleep disorders and the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS
The company news service from the London Stock Exchange